New analysis links vaginal estrogen prescriptions in women with recurrent urinary tract infections to lower rates of sepsis, hospitalization and death over the following years. Low-dose vaginal estrogen is applied locally and is minimally absorbed into the bloodstream. It compared women with recurrent urinary tract infections who received a vaginal estrogen prescription against those who did not, following outcomes over eight years. No randomized trial has been powered to determine whether vaginal estrogen affects heart disease, cancer or blood clots. Only 9.0% filled a vaginal estrogen prescription, at a median of 15 months after diagnosis.